Study of the Effect of N-acetyl Cysteine on the Renal Graft Function Biomarkers (IL18, NGAL)

Overview

The purpose of this study is to investigate the effect of (NAC) N-Acetyl Cysteine on biomarkers of Delayed Graft Function (DGF), including Neutrophil Gelatinase Associated Lipocalin (NGAL) and Intereleukin 18 (IL18).

Full Title of Study: “Phase 3 Study of N-acetyl Cysteine as an Antioxidant and Glutathione Synthesis Inducer on Biomarkers of Delayed Renal Graft Function Including NGAL and IL-18”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: April 2012

Detailed Description

Kidney transplantation is the best treatment for most patients with end stage renal failure, but limited numbers of suitable kidneys are available for transplantation. So preservation of graft is vital. This necessitates the studies and interventions to improve outcome of renal transplantation surgery. Delayed Graft Function (DGF) or delay in performance of transplanted kidney means absence of acceptable function in the renal activity in postgrafting phase. DGF is a consequence of ischemic and reperfusion injuries (IRI), and oxygen free radicals have a main role in pathophysiology of DGF. In meta-analysis studies, it has been demonstrated that DGF has a correlation with long and short time graft survival. Despite great advances in the transplantation procedure, dysfunction prevalence has not decreased. Major causes of this problem are the lack of appropriate markers for early diagnosis of DGF and on the other hand lack of appropriate and effective interventions to controll DGF. Studies have shown that N-Acetyl Cysteine (NAC) can induce GSH synthesis, scavenger of free radicals, and infusion of NAC had similar effects as glutathione. This is a randomized clinical trial (RCT) on patients who have received kidney transplantation from living donors. Sixty transplanted patients will be randomized into 2 groups. The first group of patients will be treated with NAC 600mg 6 hr before transplantation and two doses of NAC 12 hours apart after transplantation in addition to standard treatment, and the second group will receive only standard antirejection treatment. For all patients entered the study, urinary concentrations of IL18 and NGAL will be measured in designated times. Risk factors of DGF will be compared in two groups and effectiveness of NAC in reducing DGF will be determined.

Interventions

  • Drug: N-acetyl Cysteine
    • 600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.

Arms, Groups and Cohorts

  • Active Comparator: N-Acetyl Cysteine
    • N-Acetyl Cysteine: receive N-Acetyl Cysteine in addition to standard treatment
  • No Intervention: standard treatment
    • This group is without N-Acetyl Cysteine : just receives standard treatment

Clinical Trial Outcome Measures

Primary Measures

  • renal function biomarkers (IL18, NGAL)difference between study and control group in 4 and 24 hr after transplantation
    • Time Frame: 4 and 24 hrs after renal graft

Secondary Measures

  • dialysis
    • Time Frame: 60 days after transplantation

Participating in This Clinical Trial

Inclusion Criteria

  • patient receiving transplantation from living donors Exclusion Criteria:

  • having a neoplastic disease – brain tumor – having inflammatory diseases in their active phase (SLE) – an acute infection, meningitis, sepsis – Sickle Cell Disease – Pregnancy – Cardio-renal syndrome – endogenous Cushing's syndrome – chronic use of cimetidine – a history of acute pancreatitis in recent months – Multiple Sclerosis – cardiac bypass in a recent month – cirrhosis due to Hepatitis C – having Alzheimer's disease – having a untreated major depressive illness or schizophrenia – Stroke in recent months – Hyperoxaluria – sensitivity to sulfonamides

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shahid Beheshti University of Medical Sciences
  • Provider of Information About this Clinical Study
    • Jamshid Salamzadeh/Dr, Shaheed Beheshti Medical University
  • Overall Official(s)
    • Jamshid Salamzadeh, PhD, Study Director, SBMU School of Pharmacy, Tehran, Iran
  • Overall Contact(s)
    • Jamshid Salamzadeh, PhD, 00982188662334, j.salamzadeh@yahoo.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.